pseudomonas aeruginosa pa14

SPR206 is a polymyxin analogue and an important class of antibiotic for the treatment of bacterial infections due to multidrug resistant Gram-negative pathogen.

SPR206 acetate is a polymyxin analog that exhibits antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. By interacting with the outer membrane of the bacterium, SPR206 acetate efficiently combats bacterial infections, displaying significant efficacy with minimum inhibitory concentration (MIC) values of 0.125 mg/L against [Pseudomonas aeruginosa Pa14] and [Acinetobacter baumannii NCTC13301].

Antibacterialsynergist 3 is a dual-function biofilm inhibitor with an IC50 of 0.40 μM for PAO1 and 1.45 μM for PA14. It reduces virulence in Pseudomonas aeruginosa PAO1 by inhibiting the quorum sensing (QS) system and inducing iron deficiency. Additionally, Antibacterialsynergist 3 enhances the efficacy of Tobramycin and Ciprofloxacin in a mouse wound infection model. This compound is useful for research on Pseudomonas aeruginosa infections.

LP07 is an antibacterial agent targeting Pseudomonas aeruginosa. It exhibits a minimum inhibitory concentration (MIC) of 8 μg/mL against both wild-type and efflux pump-deficient strains of P. aeruginosa PA14. LP07 exerts its antibacterial effects by directly disrupting the structural integrity of bacterial cell membranes. It shows moderate inhibition of MMP-17 and MMP-19 but has no significant inhibitory effect on other MMP subtypes. LP07 does not inhibit LpxC enzyme activity and can be utilized in research on Pseudomonas aeruginosa infections.